Purpose: Epidermal growth factor receptor (EGFR) kinase inhibitors induce dramatic clinical
responses in a subset of non-small cell lung cancer (NSCLC) patients with advanced …

Activating epidermal growth factor receptor (EGFR) mutations have been linked with
sensitivity to gefitinib and erlotinib; however, there are no established predictive markers for …

Background Epidermal growth factor receptor (EGFR) signaling plays an important role in
non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been …

Seventy-five percent of lung adenocarcinomas with epidermal growth factor receptor (EGFR)
mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and …

Tyrosine kinase inhibitors (TKIs) have shown strong activity against non-small-cell lung
cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) …

Purpose: To examine potential markers of clinical benefit and the effects of erlotinib on the
epidermal growth factor receptor (EGFR) signaling pathway in advanced non–small cell …

A signaling pathway that is frequently deregulated in human carcinomas and has been
explored as a therapeutic target involves the activation of the epidermal growth factor …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

Non‐small‐cell lung cancers with epidermal growth factor receptor (EGFR) mutations are
sensitive to EGFR tyrosine kinase inhibitors (TKI s); however, unlike cytotoxic agents, it is …

Purpose To evaluate the relationship between treatment efficacy and exposure of total and
unbound erlotinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal …